JP2017516860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516860A5 JP2017516860A5 JP2017515005A JP2017515005A JP2017516860A5 JP 2017516860 A5 JP2017516860 A5 JP 2017516860A5 JP 2017515005 A JP2017515005 A JP 2017515005A JP 2017515005 A JP2017515005 A JP 2017515005A JP 2017516860 A5 JP2017516860 A5 JP 2017516860A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- compound
- patient
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 38
- 150000001875 compounds Chemical class 0.000 claims description 29
- 101150018624 ARF6 gene Proteins 0.000 claims description 27
- 101100379471 Drosophila melanogaster Arf51F gene Proteins 0.000 claims description 27
- 239000003112 inhibitor Substances 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 12
- 230000033115 angiogenesis Effects 0.000 claims description 11
- 230000002792 vascular Effects 0.000 claims description 11
- 208000035868 Vascular inflammations Diseases 0.000 claims description 10
- 125000001475 halogen functional group Chemical group 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 208000022873 Ocular disease Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 206010069351 acute lung injury Diseases 0.000 claims description 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 208000030533 eye disease Diseases 0.000 claims description 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 206010012310 Dengue fever Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims description 2
- 206010061192 Haemorrhagic fever Diseases 0.000 claims description 2
- 208000008913 Hantavirus Infections Diseases 0.000 claims description 2
- 208000001344 Macular Edema Diseases 0.000 claims description 2
- 206010025415 Macular oedema Diseases 0.000 claims description 2
- 208000030156 Marburg disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 206010038687 Respiratory distress Diseases 0.000 claims description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000025729 dengue disease Diseases 0.000 claims description 2
- 208000029629 hantavirus infectious disease Diseases 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 201000010230 macular retinal edema Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462003355P | 2014-05-27 | 2014-05-27 | |
| US62/003,355 | 2014-05-27 | ||
| PCT/US2015/032720 WO2015183989A1 (en) | 2014-05-27 | 2015-05-27 | Arf6 inhibitors and methods of synthesis and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017516860A JP2017516860A (ja) | 2017-06-22 |
| JP2017516860A5 true JP2017516860A5 (enExample) | 2018-07-05 |
Family
ID=54699729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515005A Pending JP2017516860A (ja) | 2014-05-27 | 2015-05-27 | Ａｒｆ６阻害剤並びにそれらの合成方法及び使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10849901B2 (enExample) |
| EP (1) | EP3148986A4 (enExample) |
| JP (1) | JP2017516860A (enExample) |
| WO (1) | WO2015183989A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017112777A1 (en) | 2015-12-22 | 2017-06-29 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| WO2018222473A1 (en) * | 2017-06-01 | 2018-12-06 | Albert Einstein College Of Medicine, Inc. | Bax activators and uses thereof in cancer therapy |
| KR102736865B1 (ko) | 2017-06-21 | 2024-12-03 | 샤이 테라퓨틱스 엘엘씨 | 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물 |
| EP3672597A4 (en) * | 2017-08-21 | 2021-09-22 | Navigen, Inc. | ARF6 INHIBITORS AND RELATED PROCEDURES |
| US10738056B2 (en) | 2017-09-15 | 2020-08-11 | Aduro Biotech Inc. | Pyrazolopyrimidinone compounds and uses thereof |
| JP7407461B2 (ja) | 2018-12-19 | 2024-01-04 | シャイ・セラピューティクス・エルエルシー | がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物 |
| CN117396461A (zh) * | 2021-01-29 | 2024-01-12 | 美利坚合众国,由健康及人类服务部部长代表 | 用于靶向hrpn13的新型分子支架 |
| WO2023150619A2 (en) * | 2022-02-02 | 2023-08-10 | The Katholieke Universiteit Leuven | Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead |
| DE102022115364A1 (de) | 2022-06-21 | 2023-12-21 | Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Körperschaft des öffentlichen Rechts | FATP2 in T-Zellen als Zielmolekül zur Behandlung von Autoimmunerkrankungen |
| GB202319181D0 (en) * | 2023-12-14 | 2024-01-31 | Imperial College Innovations Ltd | Nora Inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7555571B1 (en) * | 2001-01-05 | 2009-06-30 | Palm, Inc. | Activation of mobile computing device on a cellular network |
| WO2004016271A1 (en) * | 2002-08-14 | 2004-02-26 | Axxima Pharmaceuticals Ag | Pyrimidones as antiviral agents |
| BRPI0903901A2 (pt) | 2008-04-16 | 2017-05-23 | Univ Of Utah Res Foudation | composição, métodos para inibir permeabilidade vascular, angiogênese patológica, e um mais de ativação ou disponibilidade de rac, ativação ou disponibilidade de arf6, vazamento vascular, permeabilidade vascular, angiogênese patológica e inibição de sinalde múltiplos fatores angiogênicos, de permeabilidadee inflamatórios, e, métodos para preservação de função de barreira endotelial, e para bloqueio de sinalização de vegf a jusante do receptor de vegf |
| CA2737045C (en) * | 2008-11-20 | 2017-11-14 | Bruce Kabakoff | Therapeutic protein formulations |
| US20120149710A1 (en) * | 2009-08-24 | 2012-06-14 | The Regents Of The University Of California | Sortase a inhibitors |
| CN101671336B (zh) | 2009-09-23 | 2013-11-13 | 辽宁利锋科技开发有限公司 | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 |
| WO2012065139A2 (en) * | 2010-11-11 | 2012-05-18 | Board Of Regents, The University Of Texas System | Entpd5 inhibitors |
| WO2012149157A2 (en) | 2011-04-26 | 2012-11-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| CN106458904B (zh) | 2014-06-10 | 2021-12-03 | 宇部兴产株式会社 | N-取代磺酰胺化合物及其制造方法 |
| US10441570B2 (en) | 2015-04-21 | 2019-10-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) Ligands and methods of use thereof |
| GB201604020D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| US10435429B2 (en) | 2017-10-03 | 2019-10-08 | Nucorion Pharmaceuticals, Inc. | 5-fluorouridine monophosphate cyclic triester compounds |
| WO2019113173A1 (en) | 2017-12-06 | 2019-06-13 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
-
2015
- 2015-05-27 EP EP15799998.8A patent/EP3148986A4/en not_active Withdrawn
- 2015-05-27 US US15/313,884 patent/US10849901B2/en active Active
- 2015-05-27 WO PCT/US2015/032720 patent/WO2015183989A1/en not_active Ceased
- 2015-05-27 JP JP2017515005A patent/JP2017516860A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016505637A5 (enExample) | ||
| HRP20210350T1 (hr) | Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao inhibitori plazmatskog kalikreina | |
| RU2018101473A (ru) | Депо-препарат, содержащий сложный эфир лимонной кислоты | |
| CY1123391T1 (el) | (2s)-n-[(1s)-1-kyano-2-φainyλaιθyλ]-1,4-oξazeπan-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης ι | |
| JP2016503797A5 (enExample) | ||
| CN114008035A (zh) | 一种shp2磷酸酶变构抑制剂 | |
| RU2015126015A (ru) | Новые улавливатели в лечении макулодистрофии | |
| JP2016517851A5 (enExample) | ||
| MX2020009511A (es) | Tratamiento o prevención de eventos cardiovasculares. | |
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| JP2015521189A5 (enExample) | ||
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| JP2016516074A5 (enExample) | ||
| EA201370230A1 (ru) | Новые ингибиторы rock | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| CY1110373T1 (el) | Συνεργιστικος συνδυασμος που περιλαμβανει ροφλουμιλαστη και εναν αντιχολινεργικο παραγοντα που επιλεγεται απο αλατα τιοτροπιου για την θεραπεια αναπνευστικων ασθενειων | |
| NZ708526A (en) | Novel rock inhibitors | |
| JP2014502641A5 (enExample) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JOP20210329A1 (ar) | مركبات بيرازول مزدوجة الاستبدال كمثبطات كيتو هيكسو كيناز | |
| JP2015535247A5 (enExample) | ||
| JP2013534527A5 (enExample) | ||
| EA025948B1 (ru) | КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR | |
| RU2017112303A (ru) | Способ применения комбинации нового производного гидроксамовой кислоты и антибактериального вещества |